Introduction: Welcome to the world of Vonoprazan Fumarate, a groundbreaking medication designed to provide relief and management of acid-related disorders. Vonoprazan Fumarate is a potent proton pump inhibitor (PPI) that offers a novel approach to reducing gastric acid secretion. This innovative medication is a valuable tool in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions arising from excessive stomach acid production. Let's delve into the benefits and applications of Vonoprazan Fumarate in empowering acid-related disorder management.
The Power of Vonoprazan Fumarate: Vonoprazan Fumarate's mechanism of action centers on inhibiting the H+/K+ ATPase proton pump, an enzyme responsible for the secretion of gastric acid. Unlike traditional PPIs, Vonoprazan Fumarate offers rapid and sustained acid suppression, making it a potent option for managing acid-related disorders.
Benefits of Vonoprazan Fumarate:
1:GERD Relief: Vonoprazan Fumarate is particularly effective in providing relief from the symptoms of gastroesophageal reflux disease (GERD), including heartburn and regurgitation.
2:Peptic Ulcer Healing: Vonoprazan Fumarate aids in the healing and prevention of peptic ulcers by reducing stomach acid secretion and creating an environment conducive to tissue repair.
3:Helicobacter pylori Eradication: In combination with antibiotics, Vonoprazan Fumarate can be used to help eradicate Helicobacter pylori bacteria, a common cause of peptic ulcers.
4:Maintenance Therapy: Vonoprazan Fumarate is suitable for long-term maintenance therapy to prevent recurrence of GERD symptoms or peptic ulcers.
5:Diverse Applications: Vonoprazan Fumarate is a versatile medication that offers benefits in various acid-related disorders, providing relief and improving the quality of life for affected individuals.
Product Name |
(E)-but-2-encdioic acid J-[5-(2-fluorophenyl)-1 - pyridin-3-ylsul fbnylpyrrol-3-yl]-N-methylmctha namine |
|||
CAS NO. |
1260141-27-2 |
Mfg Date |
Apr.06,2023 |
|
Batch NO. |
2M024230401 |
Inspection Date |
Apr. 13,2023 |
|
Production Lot Size |
50.55Kg |
Report Date |
Apr.25,2023 |
|
Packing Specification |
25Kg/drum |
Retest Date |
Apr.05,2023 |
|
Inspection Criteria |
Corporate Inner Quality Standards &VolumeIVolumeIVof'C.P (2020version) |
Inspection Items |
Standard |
Inspection Result |
Conclusion |
Description |
White or ofF-white crystalline powder |
White crystalline powder |
Conforms |
Water |
<0.5% |
0.23% |
Qualified |
Melting Point |
196〜201 °C |
197.0 〜198.1 °C |
Qualified |
Residue on Ignition |
<0.1% |
0.02% |
Qualified |
Heavy Metals |
<20ppm |
Conforms 符合规定 |
Conforms |
Related substances |
Single Impurity <0.1% |
0.07% |
Qualified |
Total Impurities<0.5% |
0.24% |
Qualified |
Residual solvents |
Methanol<0.3% |
0.018% |
Qualified |
N,N-Dimcthylacctamide<0.109% |
ND |
Qualified |
|
A cctonitrile<0.041 % |
ND |
Qualified |
|
Assay |
99.0% 〜102.0% |
99.60% |
|
Conclusion |
Acoording with the standard, it conformed |
Add: Block 14, No.100, Luyun Road,Changsha 410205, Hunan, China.
Telephone: +8618688784456
Email: info@arshinepharma.com
WeChat: +8618688784456